cyc 202 has been researched along with anthranilamide in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (anthranilamide) | Trials (anthranilamide) | Recent Studies (post-2010) (anthranilamide) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 176 | 0 | 78 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhadra, K; Bhadra, U; Haritha, V; Kamal, A; Lavanya, A; Pal-Bhadra, M; Patel, N; Pushpavalli, SN; Ramaiah, MJ; Tamboli, JR | 1 |
1 other study(ies) available for cyc 202 and anthranilamide
| Article | Year |
|---|---|
Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; M Phase Cell Cycle Checkpoints; MicroRNAs; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; ortho-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Purines; Pyrazoles; Pyrimidines; Roscovitine; Tumor Suppressor Protein p53 | 2013 |